G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 3.78 EUR -1% Market Closed
Market Cap: 189m EUR
Section:
 

Relative Value

The Relative Value of one GNFT stock under the Base Case scenario is 5.38 EUR. Compared to the current market price of 3.78 EUR, Genfit SA is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GNFT Relative Value
Base Case
5.38 EUR
Undervaluation 30%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

4.2
P/S
P/S
Price to Sales
4.2
vs History
47
vs Industry
77
Median 3Y
4
Median 5Y
4
Industry
7.6
Forward
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
11
Median 3Y
-4.4
Median 5Y
-1.4
Industry
24.3
Forward
-96.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
14
Median 3Y
-3
Median 5Y
-2.5
Industry
22
More Details
3.5
P/FCFE
P/FCFE
Price to FCFE
3.5
vs History
9
vs Industry
10
Median 3Y
-2.6
Median 5Y
-1.5
Industry
24.3
More Details
3.6
P/B
P/B
Price to Book Value
3.6
vs History
14
vs Industry
46
Median 3Y
2.4
Median 5Y
2.2
Industry
3.2
More Details
1.9
EV/S
EV/S
Enterprise Value to Sales
1.9
vs History
60
vs Industry
67
Median 3Y
2.8
Median 5Y
3.1
Industry
8.4
Forward
1.2
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
60
vs Industry
70
Median 3Y
2.8
Median 5Y
3.3
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
13
Median 3Y
-3
Median 5Y
-2.1
Industry
6.2
Forward
5.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
11
Median 3Y
-2.8
Median 5Y
-2
Industry
6.7
Forward
3.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
17
Median 3Y
-2.5
Median 5Y
-1.7
Industry
8.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
13
Median 3Y
-2.4
Median 5Y
-1.7
Industry
6.6
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
82
vs Industry
50
Median 3Y
1.9
Median 5Y
1.9
Industry
5.3
More Details

Multiples Across Competitors

GNFT Competitors Multiples
Genfit SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Genfit SA
PAR:GNFT
189m EUR 4.2 -4.9 -3.3 -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 246 369.5 -162 767.9 -197 652.2 -195 396.7
US
Abbvie Inc
NYSE:ABBV
413.6B USD 6.9 176.2 17 24.1
US
Amgen Inc
NASDAQ:AMGN
183.9B USD 5.1 26.3 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
156.4B USD 5.4 19.3 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.6B USD 9.4 30.1 22 23
US
Epizyme Inc
F:EPE
94.1B EUR 2 057.1 -524.9 -571.6 -556.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.1B USD 5.3 16.4 15.6 17.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.6B USD 24.6 -189.9 -475.2 -326.2
AU
CSL Ltd
ASX:CSL
87.2B AUD 3.6 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
48.8B EUR 15.7 36.9 64 65.8
P/S Multiple
Revenue Growth P/S to Growth
FR
G
Genfit SA
PAR:GNFT
Average P/S: 3 113 500.6
4.2
-6%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 246 369.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.9
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
10%
0.9
US
E
Epizyme Inc
F:EPE
2 057.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
5%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.6
44%
0.6
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
15.7
46%
0.3
P/E Multiple
Earnings Growth PEG
FR
G
Genfit SA
PAR:GNFT
Average P/E: 46.3
Negative Multiple: -4.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 767.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
176.2
89%
2
US
Amgen Inc
NASDAQ:AMGN
26.3
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.3
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -524.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
8%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -189.9 N/A N/A
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
36.9
37%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
G
Genfit SA
PAR:GNFT
Average EV/EBITDA: 23.3
Negative Multiple: -3.3
49%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 652.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -571.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
9%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -475.2 N/A N/A
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
64
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
G
Genfit SA
PAR:GNFT
Average EV/EBIT: 25.5
Negative Multiple: -3.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 396.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -326.2 N/A N/A
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
65.8
N/A N/A

See Also

Summary
GNFT intrinsic value, competitors valuation, and company profile.
DCF Valuation
GNFT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GNFT stock valuation using valuation multiples.
Wall Street Estimates
GNFT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GNFT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 297,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.